METHOD FOR SURGICAL MANAGEMENT OF THROUGH MACULAR RUPTURES USING AUTOLOGOUS PLATELET-RICH PLASMA
2023-04-19
专利权人RUSSIAN FEDERATION MIN HEALTH CHILDRENS (RUHE-Non-standard)
申请日期2023-04-19
专利号RU2830805-C2
成果简介NOVELTY - Invention refers to medicine, namely to ophthalmosurgery, and can be used in surgical treatment of through macular retinal ruptures by blocking rupture with autologous platelet-rich plasma (PRP). That is ensured by sampling 10 ml of patient’s venous blood immediately before the operation. Transconjunctival sutureless three-port vitrectomy 25 G is performed. A posterior hyaloid membrane and an internal boundary membrane are removed. One drop of the PRP fraction, which is the richest in thrombocytes, is applied on the macular area at the rupture without trying to get into the hole itself. Formed pulp-like PRP is moved directly into the rupture with forceps or shifted by the tip of the vitreous tube, completely filling its cavity. Excess PRP is removed from the macular region with the help of a vitreotome, and the intervention is completed by air tamponade. USE - Medicine. ADVANTAGE - Invention provides higher efficiency of surgical intervention due to achievement of complete closure of rupture and improvement of visual functions, reduction of traumatism of operation due to provision of complete blocking of rupture by plasma without trauma of retinal area and choroid with cannulas, reducing the risk of postoperative complications by removing excess PRP from the macular surface, which eliminates the risk of part of the PRP coming out into the anterior chamber with formation of fibrin films. 1 cl, 1 ex
IPC 分类号A61F-009/007 ; A61K-035/19 ; A61P-027/02
国家俄罗斯
专业领域生物科学
语种英语
成果类型专利
文献类型科技成果
条目标识符http://119.78.100.226:8889/handle/3KE4DYBR/21994
专题中国科学院新疆生态与地理研究所
作者单位
RUSSIAN FEDERATION MIN HEALTH CHILDRENS (RUHE-Non-standard)
推荐引用方式
GB/T 7714
VELICHKO P B,FABRIKANTOV O L. METHOD FOR SURGICAL MANAGEMENT OF THROUGH MACULAR RUPTURES USING AUTOLOGOUS PLATELET-RICH PLASMA. RU2830805-C2[P]. 2023.
条目包含的文件
条目无相关文件。
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。